Johann de Bono completed a medical degree at Glasgow University Medical School in Scotland, trained in internal medicine, and graduated as a Member of the Royal College of Physicians (MRCP). He was awarded a PhD after a four-year Cancer Research UK Clinical Research PhD fellowship and completed a Masters degree in medical oncology at Glasgow University. He was awarded a Royal College of Physicians travelling scholarship to conduct research at the Southwest Oncology Group statistical headquarters at the Fred Hutchinson Cancer Center (Seattle, Washington). He then spent three further years at The Institute for Drug Development (San Antonio, Texas), and the University of Texas Health Science Center (San Antonio, Texas) after which he moved to the Royal Marsden and the Institute of Cancer Research in London and Sutton.
His current position is Professor of Experimental Cancer Medicine, Honorary Consultant Medical Oncologist at the Royal Marsden Hospital and Institute of Cancer Research, London, England.
A Fellow of both the Royal College of Physicians in London and the Royal College of Physicians and Surgeons of Glasgow, Professor de Bono has received many awards during his career, including the American Society for Clinical Oncology (ASCO) Young Investigator Award, an ASCO Merit Award, and a Doris Duke Charitable Foundation Clinician-Scientist Faculty Award as well as an ESMO Award. Professor de Bono has been awarded research grants from the Cancer Research Campaign, Cancer Research UK, the Medical Research Council, the US National Institutes of Health, the American Association of Cancer Research, the Federation of European Cancer Societies, the American Society of Clinical Oncology, the Doris Duke Charitable Foundation, and the Mesothelioma Applied Research Foundation as well as the Prostate Cancer Foundation. In June 2012 he was elected Fellow of the Academy of Medical Sciences.
Professor de Bono’s research interests are rationally designed molecular targeted therapies and prostate cancer. He works in the clinical drug development Phase I trials program at the Royal Marsden NHS Foundation Trust Hospital, and he has been involved in the early clinical development of more than 100 novel agents—many of which are now approved drugs, including abiraterone, MDV3100 and cabazitaxel for advanced prostate cancer. He led on the first-in-man studies of olaparib that first demonstrated antitumour activity for PARP inhibitors in BRCA carrier patients. Professor de Bono has authored more than 200 peer-reviewed articles and several book chapters.
ESMO 2017 Congress
"This is an exciting time in prostate cancer medicine with many new advances that are highly likely to further impact the treatment of men suffering from this common cancer. I am confident that the Prostate Cancer Track will shed further light on how we best care for our patients suffering from these malignant and molecularly diverse diseases."
Johann de Bono
Johann de Bono was the Prostate Cancer Track Chair of the ESMO 2017 Congress, which took place in Madrid, Spain (8-12 September 2017).